19 results

  • Aimovig

    (erenumab-aooe)
    Amgen Inc
    Usage: AIMOVIG is indicated for the preventive treatment of migraines in adults.

  • Amjevita

    (adalimumab-atto)
    Amgen Inc
    Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

  • Avsola

    (infliximab-axxq)
    Amgen Inc
    Usage: AVSOLA is indicated for reducing signs and symptoms, inducing and maintaining remission in moderately to severely active Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), and other conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.

  • Bkemv (eculizumab-aeeb)

    (eculizumab-aeeb)
    Amgen Inc
    Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.

  • Blincyto

    (blinatumomab)
    Amgen Inc
    Usage: BLINCYTO is indicated for treating CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adults and pediatric patients (≥1 month) during first or second remission with minimal residual disease (MRD ≥0.1%), as well as in cases of relapsed or refractory ALL and during the consolidation phase of chemotherapy.

  • Corlanor

    (ivabradine)
    Amgen Inc
    Usage: Corlanor is indicated to reduce hospitalization risk for adults with stable, symptomatic chronic heart failure (left ventricular ejection fraction ≤ 35%) and resting heart rate ≥ 70 bpm. It is also used for pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy.

  • Evenity

    (romosozumab-aqqg)
    Amgen Inc
    Usage: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, including those with a history of osteoporotic fractures or multiple risk factors. Treatment is limited to 12 monthly doses, after which anti-resorptive therapy should be considered.

  • Imdelltra (amg757)

    (Tarlatamab-dlle)
    Amgen Inc
    Usage: IMDELLTRA is indicated for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) that has progressed after platinum-based chemotherapy. This indication is based on accelerated approval, contingent upon further verification of clinical benefit in confirmatory trials.

  • Imlygic

    (talimogene laherparepvec)
    Amgen Inc
    Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients with recurrence after surgery. It does not improve overall survival or affect visceral metastases.

  • Lumakras

    (sotorasib)
    Amgen Inc
    Usage: LUMAKRAS is indicated for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy. It is also indicated in combination with panitumumab for KRAS G12C-mutated metastatic colorectal cancer (mCRC) after specific chemotherapy.